[Use of carvedilol in daily practice].
Studies conducted over recent years have definitively confirmed beta-blockers as the major treatment for heart failure. However, they are difficult to use and, to date, only carvedilol has been granted a Marketing Authorisation for this indication. The practical aspects of treatment with carvedilol in these patients are reviewed.
Cohen-Solal
A
A
Service de Cardiologie, Hôpital Beaujon, 100, boulevard du Général Leclerc, 92110 Clichy, France.
Logeart
D
D
Guiti
C
C
Bourgoin
P
P
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D001919:Bradycardia / Q000150:complications; D002227:Carbazoles / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D002309:Cardiology / Q000379:methods; D000077261:Carvedilol; D003327:Coronary Disease / Q000150:complications; D016903:Drug Monitoring / Q000379:methods; D004363:Drug Utilization; D005602:France; D006333:Heart Failure / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007022:Hypotension / Q000150:complications; D018579:Patient Selection; D011237:Predictive Value of Tests; D011412:Propanolamines / Q000494:pharmacology / Q000600:supply & distribution / Q000627:therapeutic use*; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol